Writing the Executive Summary in a PBRER

Introduction

The Executive Summary is often the first scientific section read by regulatory assessors and senior reviewers. Although positioned at the beginning of the PBRER, it is usually one of the last sections prepared because it summarises the conclusions reached throughout the completed report.

A well-written Executive Summary provides a concise but scientifically balanced overview of the reporting interval. It should allow a reviewer to understand the major developments affecting the medicinal product, the principal safety findings, important benefit considerations and the overall conclusions regarding the benefit-risk balance without reading the entire report. At the same time, it should accurately reflect the detailed discussions presented elsewhere in the document and should never introduce information that is not supported by subsequent sections.

Preparing an effective Executive Summary therefore requires judgement rather than summarisation. The author must determine which findings are sufficiently important to warrant inclusion, how much emphasis each issue deserves and how the various scientific observations should be integrated into a coherent overview of the reporting period.

Regulatory Basis

The structure and content of the Executive Summary are described within ICH E2C(R2) and reflected within GVP Module VII for Periodic Safety Update Reports prepared within the European Union.

Neither guidance specifies the exact wording that should be used. Instead, the guidance describes the purpose of the section and the information expected to be communicated. Consequently, authors retain considerable responsibility for determining how best to summarise the scientific assessment while ensuring that the summary remains balanced, accurate and proportionate.

The Executive Summary should therefore be regarded as a scientific synopsis rather than a regulatory form. It should communicate the principal conclusions of the report in language that is sufficiently concise for senior reviewers while remaining scientifically accurate and fully supported by the detailed discussions that follow.

Regulatory Basis

• ICH E2C(R2): Executive Summary.
• EMA Good Pharmacovigilance Practices (GVP) Module VII.

Purpose of the Executive Summary

The Executive Summary serves several important functions within the PBRER.

First, it provides regulators with an overview of the reporting interval, highlighting the scientific issues that have influenced preparation of the report. Second, it summarises the principal benefit and risk findings without requiring immediate review of the complete document. Third, it introduces the integrated benefit-risk conclusions that are explored in greater detail later in the report.

The Executive Summary should not attempt to replace the detailed scientific discussions contained elsewhere within the report. Rather, it should guide the reader towards the principal conclusions while maintaining consistency with the evidence presented in subsequent sections.

A useful way to approach the Executive Summary is to consider the questions that a regulatory assessor wishes to answer immediately after opening the report.

• What were the most important developments during this reporting period?
• Did any significant new safety concerns emerge?
• Were there important changes to the understanding of known risks?
• Has new information altered the benefit-risk balance?
• Were important regulatory actions taken?
• Does the Marketing Authorisation Holder propose any further action?

If these questions can be answered clearly after reading the Executive Summary, the section has usually achieved its purpose.

Writing Tip

The Executive Summary should summarise the scientific assessment, not the report itself. Readers are interested in understanding what changed during the reporting interval rather than reading a list of sections contained within the document.

Developing the Executive Summary

Although the Executive Summary appears first within the completed PBRER, experienced authors rarely write it first.

Instead, the section is usually drafted after completion of the detailed scientific discussions and refined following the integrated benefit-risk evaluation. This approach allows the author to ensure that the summary accurately reflects the final conclusions of the report and remains consistent with all preceding sections.

Before drafting begins, it is often useful to identify the five or six principal scientific messages arising from the reporting interval. These may include completion of important signal evaluations, new safety information from post-authorisation studies, significant regulatory actions, important product information updates or conclusions affecting the overall benefit-risk balance.

These key messages then become the framework around which the Executive Summary is developed.

The objective is not to mention every issue discussed within the report but to communicate the issues most relevant to regulatory assessment of the medicinal product during the reporting interval.

How Regulatory Assessors Use the Executive Summary

The Executive Summary serves as the initial scientific overview of the PBRER and often shapes the assessor's expectations before detailed review begins. Although regulatory reviewers will examine the complete report, the Executive Summary provides an early indication of the major scientific issues addressed during the reporting interval and the Marketing Authorisation Holder's overall interpretation of the available evidence.

The summary should therefore enable the assessor to understand, within a relatively short section, whether important new safety information has emerged, whether existing risks have been re-evaluated, whether regulatory actions have occurred and whether the overall benefit-risk balance has changed. It should also identify any significant conclusions that will be explored in greater detail later in the report.

Assessors commonly compare the Executive Summary with the integrated benefit-risk evaluation and the concluding sections of the report. Any inconsistency between these sections may prompt additional scrutiny during scientific assessment. Consequently, the Executive Summary should be reviewed carefully after completion of the entire report to ensure that it accurately reflects the final scientific conclusions.

Inspection Insight

During regulatory assessment, reviewers frequently compare the Executive Summary with the detailed discussions that follow. Significant conclusions introduced in the summary should be supported by evidence presented elsewhere in the report, while important findings described later should not be omitted from the summary without justification.

Scientific Principles Underpinning the Executive Summary

Although concise, the Executive Summary should reflect the same scientific principles that apply throughout the remainder of the PBRER.

The discussion should remain evidence-based, balanced and proportionate to the importance of the findings. Scientific interpretation should take precedence over description, and emphasis should be given to developments that materially influence understanding of the medicinal product's benefit-risk profile.

The Executive Summary should also maintain cumulative perspective. The objective is not simply to describe events occurring during the reporting interval but to explain how those events contribute to the evolving understanding of the product. Findings that do not alter the current scientific assessment generally require only limited discussion, whereas developments with potential regulatory implications should receive appropriate emphasis.

Authors should avoid language suggesting certainty where uncertainty remains. Equally, established conclusions supported by substantial evidence should not be presented as speculative. The language used throughout the Executive Summary should accurately reflect the strength of the available evidence.

Selecting Information for Inclusion

Determining what should be included in the Executive Summary is often more challenging than writing the summary itself. Most reporting intervals generate substantially more information than can reasonably be discussed within a concise overview. Effective authors therefore distinguish between information that is scientifically important and information that is simply available.

Topics commonly considered for inclusion include significant completed signal evaluations, important regulatory actions, clinically meaningful changes to identified or potential risks, relevant findings from post-authorisation safety studies, important benefit information and any conclusions affecting the overall benefit-risk assessment.

By contrast, routine operational activities that do not materially influence the scientific conclusions of the report generally require little or no discussion within the Executive Summary. Their detailed description belongs within the appropriate sections of the PBRER rather than within the opening synopsis.

The emphasis given to each topic should reflect its scientific and regulatory importance. The Executive Summary should therefore not be regarded as a checklist but as a balanced overview of the reporting interval.

Writing Tip

A useful question during drafting is:

If this paragraph were removed, would the regulator's understanding of the overall benefit-risk assessment change?

If the answer is no, the information may be better placed elsewhere in the report.

Maintaining Balance

One of the most important characteristics of a well-written Executive Summary is balance.

The summary should neither minimise important safety findings nor exaggerate isolated observations that have limited impact on the overall benefit-risk profile. Instead, the discussion should present the available evidence objectively and in appropriate clinical context.

Balance also applies to the relationship between benefits and risks. Authors should avoid concentrating exclusively on safety findings while overlooking relevant benefit information where this contributes to interpretation of the overall benefit-risk balance. Similarly, discussion of benefits should not be used to diminish the importance of emerging safety concerns where additional pharmacovigilance activities or regulatory actions may be required.

The Executive Summary should therefore provide an accurate reflection of the integrated scientific assessment presented throughout the remainder of the report.

Common Mistakes When Writing the Executive Summary

Although the Executive Summary is relatively short compared with the remainder of the PBRER, it is often one of the most frequently revised sections during medical review. Many of the deficiencies identified arise because authors misunderstand the purpose of the section. The objective is not to produce an abbreviated version of the report but to communicate the principal scientific conclusions of the reporting interval in a balanced and coherent manner.

One common mistake is attempting to summarise every section of the PBRER. This frequently produces a lengthy document containing numerous factual statements but very little scientific interpretation. The Executive Summary should instead focus on the developments that materially influence understanding of the medicinal product's benefit-risk profile.

Another frequent problem is inconsistency with the detailed discussions presented elsewhere within the report. New conclusions should not appear for the first time in the Executive Summary, nor should important scientific findings discussed later in the report be omitted without appropriate justification. The Executive Summary should faithfully reflect the completed scientific assessment rather than introduce independent interpretations.

Authors should also avoid using unnecessarily definitive language where scientific uncertainty remains. Aggregate reporting frequently involves interpretation of evolving evidence, and the degree of confidence expressed within the summary should accurately reflect the strength of the supporting data.

Finally, excessive detail should be avoided. Numerical data, detailed case descriptions and extensive discussion of individual studies generally belong within the relevant sections of the report. The Executive Summary should communicate the scientific implications of these findings rather than reproduce the underlying evidence.

Common Mistake

Writing the Executive Summary before completing the remainder of the PBRER frequently results in inconsistencies and repeated revisions. Most experienced authors prepare this section only after the integrated benefit-risk evaluation has been finalised.

Relationship to Other Sections of the PBRER

The Executive Summary occupies a unique position within the report because it reflects the conclusions developed throughout all subsequent sections.

Its content should therefore remain closely aligned with the integrated benefit-risk evaluation, the conclusions and actions section, and the principal scientific discussions contained elsewhere in the document. Changes made during medical review of later sections frequently require corresponding revisions to the Executive Summary to maintain consistency.

Authors should resist the temptation to treat the Executive Summary as an isolated chapter. Every important statement included within the summary should be traceable to detailed discussion presented elsewhere in the report. Similarly, every major conclusion developed during the report should be reflected appropriately within the Executive Summary.

Maintaining this alignment requires one final review after completion of the report to ensure that the summary accurately represents the final scientific position of the Marketing Authorisation Holder.

Key Takeaways

The Executive Summary is a concise scientific synopsis of the completed PBRER rather than a shortened version of the report template.

It should communicate the principal scientific developments affecting the medicinal product during the reporting interval and explain whether those developments alter the overall benefit-risk balance.

The summary should be prepared after completion of the detailed scientific assessment and should remain fully consistent with the conclusions presented throughout the remainder of the report.

Good Executive Summaries are characterised by clarity, balance, scientific objectivity and proportionate emphasis on the issues most relevant to regulatory assessment.

Continue Reading

The next article in this series examines the first substantive section of the PBRER.

Recommended next article:

• [[writing-the-worldwide-marketing-authorisation-status-section]]

Related articles:

• [[understanding-the-structure-of-a-pbrer]]
• [[how-to-write-a-pbrer]]
• [[pbrer-guide]]
• [[writing-the-actions-taken-for-safety-reasons-section]]

References

Primary Regulatory References

1. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report.

2. EMA Good Pharmacovigilance Practices (GVP) Module VII – Periodic Safety Update Reports.

3. EMA Questions and Answers on Periodic Safety Update Reports.